Effect of Actonel on Periodontal Health of Postmenopausal Women
Information source: University Hospital Case Medical Center
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Periodontal Disease
Intervention: Risedronate (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University Hospital Case Medical Center Official(s) and/or principal investigator(s):
james liu, md, Principal Investigator, Affiliation: UHCMC
leena palomo, dds msd, Principal Investigator, Affiliation: uhcmc
Overall contact:
leena palomo, dds msd, Phone: 2163686300, Email: leena.palomo@case.edu
Summary
Hypothesis: Women who use Actonel (risedronate) for osteopenia will show beneficial
periodontal effects.
Clinical Details
Official title: Effect of Actonel on Periodontal Health of Postmenopausal Women
Study design: Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: Periodontal alveolar bone changes
Secondary outcome: Periodontal attachment levels
Detailed description:
Women who use Actonel for osteopenia will show beneficial attachment loss, alveolar bone
height and morphology as compared to those who do not when oral hygiene is corrected for.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Osteopenia
- Postmenpausal
Exclusion Criteria:
- Male
- Diabetes
Locations and Contacts
leena palomo, dds msd, Phone: 2163686300, Email: leena.palomo@case.edu
Uhcmc, cleveland, Ohio 44124, United States; Recruiting
james liu, md, Principal Investigator
Additional Information
Starting date: January 2008
Ending date: January 2011
Last updated: January 14, 2008
|
